A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Entospletinib (Primary)
- Indications Leukaemia; Lymphoma
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 13 Feb 2018 Status changed from recruiting to completed.
- 09 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 09 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.